Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
351. |
ECCT/16/05/01 | A5338 A5338 An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) |
Principal Investigator(s) 1. David Schnabel Site(s) in Kenya KISUMU CRS |
View |
352. |
ECCT/16/04/01 | HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection HVTN 703/HPTN 081 A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection |
Principal Investigator(s) 1. Dr. Victor Akelo Akelo Site(s) in Kenya KISUMU CRS |
View |
353. |
ECCT/16/03/02 | Infant TB Infection Prevention Study (“iTIPS”) Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants |
Principal Investigator(s) 1. Grace John-Stewart Site(s) in Kenya 1. Kisumu East District Hospital (Kisumu county) 2. Ahero County Hospital (Kisumu county) 3. Bondo sub-County Hospital (Kisumu county) |
View |
354. |
ECCT/16/02/06 | A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults. A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP] |
Principal Investigator(s) 1. Christina Wesonga Obiero Site(s) in Kenya Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme |
View |
355. |
ECCT/16/02/05 | PfSPZ Malaria Vaccine Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months through 12 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age de-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy |
Principal Investigator(s) 1. Martina Oneko 2. Mary J Hamel Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Wagai Health Center (Siaya county) |
View |